Hypopituitarism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Iqra Qamar (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
*Secondary prevention may be done by long term monitoring of patients by: | |||
**Monitoring the patients for complications of hormonal replacement therapy (under-replacement/over replacement)<ref name="pmid20210825">{{cite journal |vauthors=Harsch IA, Schuller A, Hahn EG, Hensen J |title=Cortisone replacement therapy in endocrine disorders - quality of self-care |journal=J Eval Clin Pract |volume=16 |issue=3 |pages=492–8 |year=2010 |pmid=20210825 |doi=10.1111/j.1365-2753.2009.01149.x |url=}}</ref> | |||
**Adjusting the dosages in stressful situations | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Revision as of 19:54, 11 September 2017
|
Hypopituitarism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypopituitarism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hypopituitarism secondary prevention |
|
Risk calculators and risk factors for Hypopituitarism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
- Secondary prevention may be done by long term monitoring of patients by:
- Monitoring the patients for complications of hormonal replacement therapy (under-replacement/over replacement)[1]
- Adjusting the dosages in stressful situations
Secondary Prevention
There are no secondary preventive measures available for hypopituitarism.
References
- ↑ Harsch IA, Schuller A, Hahn EG, Hensen J (2010). "Cortisone replacement therapy in endocrine disorders - quality of self-care". J Eval Clin Pract. 16 (3): 492–8. doi:10.1111/j.1365-2753.2009.01149.x. PMID 20210825.